Tests glucose sensor use in pregnant women with type 2 diabetes
Compares a continuous glucose sensor with fingerstick checks in pregnant adults with type 2 diabetes.
Key facts
- Who runs it
- University of Massachusetts, Worcester
- Where
- Worcester, United StatesSee the site
- Trial code
- Registry title
- Continuous Glucose Monitor Use in Pregnancy
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 23 May 2024
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Continuous Glucose Monitor
- Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
- Record updated
- 3 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with type 2 diabetes who are early in a single pregnancy. It compares a continuous glucose monitor with fingerstick blood sugar checks.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Type 2 diabetes confirmed by lab tests: hemoglobin A1c 6.5% (48 mmol/mol) or higher, oral glucose tolerance test 200 mg/dL (11.1 mmol/L) or higher, or fasting plasma glucose 126 mg/dL (7 mmol/L) or higher. Pregnant with one baby, 14 weeks or less at the first obstetric visit.
Main reasons for not taking part
- Type 1 diabetes
- Gestational diabetes
- Pregnant with more than one baby
- Plans prenatal care or delivery outside UMMHC
- Cannot give informed consent
This trial only enrols pregnant participants. The registry sentence this rests on: 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 1) age greater than or equal to 18 years old
- 2) singleton gestation less than or equal to 14 weeks at initial obstetric visit
- 3) established diagnosis of T2DM by laboratory criteria including hemoglobin A1c ≥6.5%, oral glucose tolerance test ≥200 mg/dL, or fasting plasma glucose ≥126 mg/dL
- 4) receiving prenatal care at UMASS Memorial Health Care (UMMHC) and plans to deliver at UMMHC
- 5) able and willing to provide informed consent
Who cannot take part
- 1) known diagnosis of type 1 diabetes or gestational diabetes
- 2) plan to receive prenatal care or delivery outside of UMMHC
- 3) inability to provide informed consent
- 4) multifetal gestation
Where in United States
- University of Massachusetts Memorial Medical CenterWorcester, United StatesContact: Gianna L Wilkie, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.
The 2 groups in the trial
- Continuous Glucose Monitoring (CGM)Treatment being tested
Patients will be randomized to application of a continuous glucose monitor (CGM). They will apply the device in the clinical setting and be instructed how to download their information onto their smartphones or using the CGM device reader. They will use the CGM for the duration of the pregnancy until delivery.
Treatment: Continuous Glucose Monitor
- Fingerstick Glucose MonitoringExisting treatment, for comparison
Patients will be randomized to checking their blood glucose with fingerstick monitors at time of fasting in the AM, and 2 hours after each meal. This is the standard of care for patients in the pregnancy diabetes clinic.
Treatment: Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Continuous Glucose Monitor Use and Perinatal Outcomes Among Pregnant Women With Type 2 Diabetes Mellitus: A Randomized Controlled Trial
- Plain-language title
- Tests glucose sensor use in pregnant women with type 2 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 August 2026